Your Good Partner in Biology Research

  1. 首頁
  2. 試劑盒
  3. 酶聯(lián)免疫試劑盒
  4. Human Mesothelin(MSLN)ELISA KIT

Human Mesothelin(MSLN)ELISA KIT

  • 中文名稱：
    人間皮素（MSLN）酶聯(lián)免疫試劑盒
  • 貨號：
    CSB-E13382h
  • 規(guī)格：
    96T/48T
  • 價格：
    ￥3600/￥2500
  • 其他：

產(chǎn)品詳情

  • 產(chǎn)品描述：
        MSLN（間皮素樣蛋白），是一種腫瘤相關(guān)抗原，廣泛表達于多種腫瘤細胞和實體瘤的細胞外基質(zhì)。MSLN的含量檢測在腫瘤診斷、預后和治療方面具有重要意義。在肺癌、卵巢癌、胰腺癌等多種癌癥中，MSLN的高表達與病情嚴重程度和預后不良相關(guān)。此外，MSLN在腫瘤細胞的增殖、侵襲和轉(zhuǎn)移中也發(fā)揮著重要作用，因此其含量檢測也可以用于預測腫瘤的侵襲和轉(zhuǎn)移風險。
        華美生物所提供的Human Mesothelin(MSLN)ELISA KIT屬于ELISA檢測試劑盒，采用雙抗夾心法定量檢測人血清、血漿、組織勻漿樣本中的MSLN，其靈敏度為15.6 pg/mL，檢測范圍為62.5 pg/mL-4000 pg/mL。
     
  • 別名：
    CAK 1 ELISA Kit; CAK1 ELISA Kit; CAK1 antigen ELISA Kit; cleaved form ELISA Kit; Megakaryocyte potentiating factor ELISA Kit; Mesothelin ELISA Kit; Mesothelin isoform 1 precursor ELISA Kit; MPF ELISA Kit; Msln ELISA Kit; MSLN_HUMAN ELISA Kit; Pre pro megakaryocyte potentiating factor ELISA Kit; Pre-pro-megakaryocyte-potentiating factor ELISA Kit; SMR ELISA Kit; SMRP ELISA Kit; Soluble MPF mesothelin related protein ELISA Kit
  • 縮寫：
  • Uniprot No.：
  • 種屬：
    Homo sapiens (Human)
  • 樣本類型：
    serum, plasma, tissue homogenates
  • 檢測范圍：
    62.5 pg/mL-4000 pg/mL
  • 靈敏度：
    15.6 pg/mL
  • 反應時間：
    1-5h
  • 樣本體積：
    50-100ul
  • 檢測波長：
    450 nm
  • 研究領(lǐng)域：
    Cancer
  • 測定原理：
    quantitative
  • 測定方法：
    Sandwich
  • 精密度：
     
  • 線性度：
     
  • 回收率：
     
  • 標準曲線：
     
  • 數(shù)據(jù)處理：
  • 貨期：
    3-5 working days

產(chǎn)品評價

靶點詳情

  • 最新研究進展：
    MSLN，全名為間皮素樣蛋白，是一種表達于腫瘤細胞表面的糖蛋白。最近的研究表明，MSLN在多種癌癥的發(fā)生和發(fā)展中發(fā)揮著重要作用，成為了一個重要的腫瘤標志物和治療靶點。對MSLN的靶向治療已成為研究的熱點之一，其中包括免疫治療、靶向藥物和基因治療等多種治療方法。
  • 功能：
    Membrane-anchored forms may play a role in cellular adhesion.; Megakaryocyte-potentiating factor (MPF) potentiates megakaryocyte colony formation in vitro.
  • 基因功能參考文獻：
    1. Elevated plasma MSLN level is related with epithelial ovarian cancer. PMID: 30319054
    2. We have demonstrated that a rising serum mesothelin is a sensitive marker of progression in the follow up of patients with MPM. PMID: 29454314
    3. we engineered variants of the fibronectin type III domain (Fn3) non-antibody protein scaffold to bind to mesothelin with high affinity, using directed evolution and yeast surface display PMID: 29738555
    4. Our goal was to stimulate antitumor immunity by combining SS1P or LMB-100 with anti-CTLA-4. We constructed a BALB/c breast cancer cell line expressing human mesothelin (66C14-M), which was implanted in one or two locations. SS1P or LMB-100 was injected directly into established tumors and anti-CTLA-4 administered i.p. In mice with two tumors, one tumor was injected with immunotoxin and the other was not. PMID: 28674083
    5. Mesothelin-targeted immunotoxin RG7787 increases pancreatic cancer cell sensitivity to taxane-mediated killing by increasing taxane-mediated microtubule stability and priming cells for apoptosis by decreasing levels of the pro-survival factor Mcl-1. PMID: 27999204
    6. RG7787 plus nab-paclitaxel is very active against primary human mesothelioma cells in vitro as well as in vivo, with serum mesothelin levels correlating with tumor response. These results indicate that this combination could be useful for treating patients with mesothelioma PMID: 27635089
    7. Efficient growth suppression in pancreatic cancer PDX model by fully human anti-mesothelin CAR-T cells. PMID: 28929447
    8. Mesothelin/mucin 16 signaling in activated portal fibroblasts regulates cholestatic liver fibrosis.( PMID: 28287406
    9. MiR-21-5p is suggested as novel regulator of MSLN with a possible functional role in cellular growth. PMID: 28125734
    10. we report herein that high tumor mesothelin expression predicts a shorter PFS and OS in EOC patients and demonstrates that serum mesothelin predicts local tumor mesothelin expression. PMID: 28160193
    11. We provide new evidence for the role of MSLN in EMT regulation, tumorigenesis and metastasis. Knockdown of MSLN led to mesenchymal to epithelial transition and less aggressive behavior of lung carcinoma and mesothelioma cells. PMID: 28288645
    12. MSLN expression increases cell migration and invasion in vitro. PMID: 27422997
    13. SMRP but not FBLN3 has a role in pleural effusions in in malignant pleural mesothelioma PMID: 28314308
    14. High mesothelin expression is associated with malignant pleural mesothelioma. PMID: 27646775
    15. Calretinin, D2-40 and mesothelin are aberrantly expressed in a proportion of CRC cases. PMID: 27062033
    16. Our results showed that IMP3 immunostaining has a higher sensitivity and specificity than mesothelin for the diagnosis of pancreatic ductal adenocarcinoma. IMP3 and mesothelin may be useful markers in distinguishing neoplastic from reactive lesions of the pancreas in instances where this is impossible by morphology alone in surgical pathology practice. PMID: 26874572
    17. Results indicate a specific mesothelin-driven tumor uptake of targeted 89zirconium-labeled antibody which visualizes mesothelin expressing pancreatic cancer in real time. PMID: 26536664
    18. Data indicate that triple-negative breast cancer (TNBC) showed the highest amplification rate (42%) in the basal-like 1 subtype. PMID: 26172299
    19. There was a trend toward elevation of SMRP values in healthy individuals exposed to asbestos compared to those without exposure. Within asbestosis cases, those with higher profusion scores had higher SMRP values than those with lower profusion scores. PMID: 26188910
    20. High mesothelin expression was strongly associated with mutant KRAS/wild-type EGFR and poor prognosis in advanced lung cancer. PMID: 26028668
    21. findings replicate association between rs1057147 and soluble mesothelin related peptide(SMRP)levels; SMRP performance as diagnostic biomarker for malignant pleural mesothelioma improved by considering genotype rs1057147; this polymorphism most likely affects a binding site for miR-611 PMID: 25436799
    22. Expression of mesothelin was observed in 42.3% of patients with triple negative breast cancer. PMID: 25776500
    23. Patients with mesothelin-positive triple negative breast carcinomas (TNBC) were older than patients with mesothelin-negative TNBC, developed more distant metastases with a shorter interval, and had significantly lower overall and disease-free survival. PMID: 25506917
    24. Delivery of mesothelin-targeted CAR T cells eradicates tumors in mice with pleural malignancies. PMID: 25378643
    25. Pleural fluid mesothelin may serve as a marker for pleural malignant mesothelioma. PMID: 25505814
    26. Patients with colon cancer had significantly higher mesothelin serum levels than the control groups. PMID: 25477701
    27. Mesothelin expression is associated with poor outcomes in breast cancer.Mesothelin is a prognostic breast tumor marker whose expression is highly enriched in triple negative breast cancer tumors. PMID: 25193277
    28. A serum mesothelin level is a prognostic indicator for patients with malignant mesothelioma in routine clinical practice. PMID: 25227779
    29. Both the serum CA125(meso) level and the ratio of the serum CA125(mesothelin) to CA125 levels (CA125(mesothelin) /CA125) were significantly higher in patients with EOC. PMID: 25197000
    30. Serum IGFBP2 and MSLN are weak diagnostic classifiers individually, but may be useful in a diagnostic biomarker panel for pancreatic cancer. PMID: 24308545
    31. MSLN-silencing caused decreased proliferation rate and reduced invasive capacity and sphere formation in MSLN-overexpressing Mero-14 cells. PMID: 24465798
    32. Being negative/focally positive for mesothelin expression was associated with longer postoperative survival than positive expression in patients with cholangiocellular carcinoma. Mesothelin positivity was a predictor of short postoperative survival. PMID: 23701154
    33. Our findings suggest that MLSN can be used as a marker of neoplastic transformation of epithelial cells in pancreatic mucinous cysts. PMID: 25125620
    34. MSLN expression in patients with early-stage lung adenocarcinoma is associated with increased risk of recurrence and reduced overall survival. PMID: 24334761
    35. These data provides evidence for the use of mesothelin as an immunogen for tumour-specific T cell response. PMID: 24520352
    36. Mesothelin provokes lymphatic invasion of colorectal adenocarcinoma. PMID: 23512344
    37. In the gastric cancer tissues, C-ERC/mesothelin expression was associated with lymphatic invasion. N-ERC/mesothelin was secreted into the supernatants of gastric cancer cell lines, but does not appear to be a useful serum marker of gastric cancer. PMID: 24146039
    38. Use of S100P and mesothelin in cytologically borderline cases can increase the diagnostic accuracy for pancreatic adenocarcinoma. PMID: 21538952
    39. Data indicate that biochemical markers significantly associated with mesothelioma were hyaluronan, N-ERC/mesothelin and syndecan-1. PMID: 23991032
    40. PE-SMRP adds some clinical information in the work-up of patients with a PE of unknown origin. PMID: 23873013
    41. Mesothelin expression was identified in 34% of patients with triple receptor negative breast cancer. PMID: 23810431
    42. addition of YKL-40 may improve the specificity of mesothelin measurements alone for detecting patients with multiple myeloma PMID: 24324091
    43. These data suggest that in difficult diagnostic cases both PAX2 and mesothelin immunohistochemical study may be useful in discriminating between PMRCC and primary pancreatic carcinoma. PMID: 24344503
    44. SMRP could improve CYFRA 21-1 antigen and carcinoembryonic antigen (CEA) accuracy in the differential diagnosis of malignant pleural mesothelioma. PMID: 23532816
    45. Mesothelin binding to CA125/MUC16 promotes pancreatic cancer cell motility and invasion via MMP-7 activation. PMID: 23694968
    46. Mesothelin, megakaryocyte potentiating factor and osteopontin are expressed in malignant mesothelioma [review] PMID: 22835614
    47. MSLN overexpression promoted the invasive potential of MCF-7 cells through ERK1/2-dependent upregulation of MMP-9; this association may have contributed to metastasis of MCF-7 cells in vivo. PMID: 23321167
    48. Data indicate that binding of mesothelin to CA125 does not alter the measurement of mesothelin for the detection of malignant mesothelioma (MM). PMID: 23357461
    49. The mesothelin expression promotes resistance to certain chemotherapy drugs such as TNF-alpha, paclitaxel, and a combination of platinum and cyclophosphamide. PMID: 22721387
    50. SMRP was lower in healthy subjects than in subjects with malignant tumors, asbestos-related pleural lesions, and other benign diseases PMID: 23277285

    顯示更多

    收起更多

  • 相關(guān)疾?。?/div>
    Antibodies against MSLN are detected in patients with mesothelioma and ovarian cancer.
  • 亞細胞定位：
    Cell membrane; Lipid-anchor, GPI-anchor. Golgi apparatus.; [Megakaryocyte-potentiating factor]: Secreted.; [Isoform 3]: Secreted.
  • 蛋白家族：
    Mesothelin family
  • 組織特異性：
    Expressed in lung. Expressed at low levels in heart, placenta and kidney. Expressed in mesothelial cells. Highly expressed in mesotheliomas, ovarian cancers, and some squamous cell carcinomas (at protein level).
  • 數(shù)據(jù)庫鏈接：

    HGNC: 7371

    OMIM: 601051

    KEGG: hsa:10232

    STRING: 9606.ENSP00000372313

    UniGene: Hs.408488